Review of enoxaparin and its clinical applications in venous and arterial thromboembolism

Bibliography

• HARVEY DM, OFFORD RH: Management of venous and cardiovascular thrombosis: enoxaparin. Hosp. Med. (2000) 61(9):628–636.
   PubMedGoogle Scholar
• FUSTER V, BADIMON L, COHEN M, AMBROSE JA, BADIMON JJ, CHESEBRO J: Insights into the pathogenesis of acute ischemic syndromes. Circulation (1988) 77(6):1213–1220.
   PubMed Web of Science ®Google Scholar
• OLER A, WHOOLEY MA, OLER J, GRADY D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA (1996) 276(10):811–815.
   PubMed Web of Science ®Google Scholar
• TIMI IIIB INVESTIGATORS: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and nonQ-wave myocardial infarction. Results of the TIMI IIIBTrial. Thrombolysis in Myocardial Ischaemia. Circulation (1994) 89(4):1545–1556.
   Google Scholar
• COHEN M: New therapies for unstable angina and nonQ-wave myocardial infarction: recent clinical trials. Am. Heart J. (1998) 135:S343–S352.
   Web of Science ®Google Scholar
• NOBLE S, SPENCER CM: Enoxaparin: a review of its clinical potential in the management of coronary artery disease. Drugs (1998) 56(2):259–272.
   PubMed Web of Science ®Google Scholar
• SPENCER F, LIU L, ZHANG Q, BALL SP, BECKER RC: Enoxaparin inhibits platelet-dependent thrombin generation in vivo in patients with unstable angina and nonQ-wave myocardial infarction. J. Am. Coll. Cardiol. (1997) 29(2 Suppl. A):304A.
   Google Scholar
• SPENCER FA, BALL SP, ZHANG Q, LIU L, BENOIT S, BECKER RC: Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization. J. Thromb. Thrombolysis (2000) 9(3):223–228.
   PubMed Web of Science ®Google Scholar
• NIGHTINGALE SL: FDA alert. JAMA (1993) 270(14):1672.
   PubMedGoogle Scholar
• FAREED J, HOPPENSTEADT DA, BICK RL: An update on heparins at the beginning of the new millennium. Semin. Thromb. Hemost. (2000) 26\(Suppl. 1):5–21.
   Google Scholar
• XIAO Z, THEROUX P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation (1998) 97:251–256.
   PubMed Web of Science ®Google Scholar
• COHEN M, THEROUX P, WEBER S et al: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int. J. Cardiol. (1999) 71(3):273–281.
   PubMed Web of Science ®Google Scholar
• •First study to investigate coadministration of enoxaparin with tirofiban in ACS.
   Google Scholar
• CURRIER JW POW TK, HAUDENSCHILD CC, MINIHAN AC, FAXON DP: Low molecular weight heparin (enoxaparin) reduced restenosis following angioplasty in the hypercholesterolemic rabbit. J. Am. Coll. Cardiol. (1991) 17(6):118B-125B.
   Google Scholar
• KIESZ RS, BUSZMAN P, MARTIN JL et al: Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial. Circulation (2001) 103:26–31.
   PubMed Web of Science ®Google Scholar
• LEADLEY RJ, KASIEWSKI CJ, BOSTWICK JS, BENTLEY R, DUNWIDDIE CT, PERRONE MH: Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin but not by unfractionated heparin. Arterioscler. Thromb. Vasubcutaneous Biol. (1998) 18(6):908–914.
   PubMed Web of Science ®Google Scholar
• FRYDMAN AIVI, BARA L, LE ROUX Y, WOLER M, CHAULIAC F, SAMAMA MM: The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. Clin. Pharmacol. (1988) 28:609–618.
   Google Scholar
• BARA L, BILLAUD E, GRAMOND G, KHER A, SAMAMA M: Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb. Res. (1985) 39(5):631–636.
   PubMed Web of Science ®Google Scholar
• COLLIGNON F, FRYDMAN A, CAPLAIN H et al.: Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb. Haemost. (1995) 73(4):630–640.
   PubMed Web of Science ®Google Scholar
• NOBLE S, PETERS DH, GOA KL: Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs (1995) 49(3):388–410.
   Google Scholar
• SAMAMA M, BERNARD P, BONNARDOT JP et al: Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br. J. Surg. (1988) 75:128–131.
   PubMed Web of Science ®Google Scholar
• ••First study to compare enoxaparin andUFH in prevention of VTE following general surgery
   Google Scholar
• GEERTS WH, HEIT JA, CLAGETT GP et al: Prevention of venous thrombo-embolism. Chest (2001) 119:132S–175S.
   Google Scholar
• SALZMAN EW, HIRSH J: The epidemiology, pathogenesis and natural history of venous thrombosis. In: Haemostasis, and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW (Eds), Lippincott, Philadelphia (1994):1275–1296.
   Google Scholar
• FRANZEC UK, SCHALCH I, JAGER KA, SCHNEIDER E, GRIMM J, BOLLINGER A: Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study). Circulation (1996) 93:74–79.
   PubMed Web of Science ®Google Scholar
• PRANDONI P, VILLALTA S, BAGATELLA Pet al: The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 82(4):423–428.
   Google Scholar
• LEVINE MN, HIRSH J, GENT Met al.: Prevention of deep vein thrombosis after elective hip surgery. Ann. Intern. Med. (1991) 114(7):545–551.
   Google Scholar
• •Study showed enoxaparin to be as effective as UFH in prophylaxis of DVT in orthopedic surgery patients.
   Google Scholar
• PLANES A, VOCHELLE N, MAZAS F et al: Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb. Haemost. (1988) 60:407–410.
   PubMed Web of Science ®Google Scholar
• BRENNER B, HOFFMAN R, BLUMENFELD Z, WEINER Z, YOUNIS JS: Gestational outcome in thrombophilic women with recurrent pregnancy loss treated with enoxaparin. Thromb. Haemost. (2000) 83:693–697.
   PubMed Web of Science ®Google Scholar
• NURMOHAMED MT, VERHAEGHE R, HAAS S et al.: A comparative trial of a low molecular weight heparin (enoxaparin)
   Google Scholar
• •• versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am. J. Surg (1995) 169:567–571.
   Google Scholar
• GAZZANIGA GM, ANGELINI G, PASTORINO G, SANTORO E, LUCCHINI M, DAL PRA ML: Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. Int. Surg. (1993) 78:271–275.
   Google Scholar
• BICK RL: Coagulation abnormalities in malignancy: a review. Semin. Thromb. Hemost. (1992) 18(4):353–372.
   PubMed Web of Science ®Google Scholar
• ENOXACAN STUDY GROUP: Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multi-centre trial with venographic assessment. Br. Surg (1997) 84:1099–1103.
   PubMed Web of Science ®Google Scholar
• ••Enoxaparin shown to be as effective andsafe as UFH in preventing DVT in cancer surgery patients.
   Google Scholar
• BERGQVIST D, AGNELLI G, COHEN AT, ELDOR A, NILSSON PE FOR THE ENOXACAN II STUDY GROUP: Prolonged prophylaxis with enoxaparin for prevention of venous thromboembolism after surgery for abdominal malignancy: the ENOXACAN II study. International Society on Thrombosis and Haemostasis. Paris, France (2001).
   Google Scholar
• ••This study shows extended enoxaparintherapy to be beneficial in cancer surgery patients.
   Google Scholar
• TURPIE AGG, LEVINE MN, HIRSH J et al.: A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl. J. Med. (1986) 315:925–929.
   PubMed Web of Science ®Google Scholar
• COLWELL CW, SPIRO TE, TROWBRIDGE AA et al.: Use of enoxaparin, a low-molecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J. Bone Joint Surg Am. (1994) 76-A(1):3–14.
   Google Scholar
• SIKORSKI JM, HAMPSON WG, STADDON GE et al.: The natural history and aetiology of deep vein thrombosis after total hip replacement. J. Bone Joint Surg. Br. (1981) 63-B(2):171–177.
   Google Scholar
• SEAGROATT V, TAN HS, GOLDACRE M, BULSTRODE C, NUGENT I, GILL L: Elective total hip replacement: incidence, emergency readmission rate and postoperative mortality. Br. Med. J. (1991) 303:1431–1435.
   PubMedGoogle Scholar
• PLANES A, VOCHELLE N, DARMON JY, FAGOLA M, BELLAUD M, HUET Y: Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet (1996) 348:224–228.
   PubMed Web of Science ®Google Scholar
• •Prolonged prophylaxis with enoxaparin following hospital discharge was shown to be beneficial in hip replacement patients in this study.
   Google Scholar
• BERGQVIST D, BENONI G, BJORGELL O et al.: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl. J. Med. (1996) 335:696–700.
   PubMed Web of Science ®Google Scholar
• FAUNO P, SUOMALAINEN O, REHNBERG Vet al.: Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin. J. Bone Joint Surg Am. (1994) 76-A(12):1814–1818.
   Google Scholar
• SPIRO TE, COLWELL CW, BONA RD et al.: Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after knee replacement surgery. Chest (1994) 106\(Suppl. 2):485.
   Google Scholar
• LECLERC JR, GEERTS WH, DESJARDINS Let al.: Prevention of venous thromboembolism after knee arthroplasty. A randomised, double-blind trial comparing enoxaparin with warfarin. Ann. Int. Med. (1996) 124:619–626.
   Google Scholar
• GEERTS WH, CODE KI, JAY RM, CHEN E, SZALAI JP: A prospective study of venous thromboembolism after major trauma. N Engl. J. Med. (1994) 331(24): 1601–1606.
   PubMed Web of Science ®Google Scholar
• GEERTS WH, JAY RM, CODE KI et al.:A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl. J. Med. (1996) 335(10):701–707.
   PubMed Web of Science ®Google Scholar
• BORRIS LC, LASSEN MR, POULSEN KA, JENSEN HP: Thromboembolic complications after hip fracture - prophylaxis with low molecular weight versus unfractionated heparin. Thromb. Haemost. (1995) 73:1104. Abstract.
   Google Scholar
• BAGLIN TP, WHITE K, CHARLES A: Fatal pulmonary embolism in hospitalised medical patients. J. Clin. Pathol. (1997) 50:609–610.
   PubMed Web of Science ®Google Scholar
• SAMAMA MM, COHEN AT, DARMON JY et al.: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl. Med. (1999) 341(10:793–800.
   PubMedGoogle Scholar
• ••Pivitol study showing efficacy ofenoxaparin 40 mg o.d. in prophylaxis of VTE in acutely ill medical patients.
   Google Scholar
• KLEBER FX, WITT C, FLOSBACH CW, KOPPENHAGEN K, VOGEL G, THE PRINCE STUDY GROUP: Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease. Thromb. Haemost. (1999) 82(Suppl.):492.
   Google Scholar
• KLEBER FX, FLOSBACH CW, KOPPENHAGEN K, VOGEL G: Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study). Circulation (1999) 100(18):I–619.
   Web of Science ®Google Scholar
• HILLBOM M, ERILA T, SOTANIEMI K et al.: Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Blood (1999) (Suppl. 1):94.
   Google Scholar
• GREER IA: Thrombosis in pregnancy: maternal and fetal issues. Lancet (1999) 353:1258–1265.
   PubMed Web of Science ®Google Scholar
• GINSBERG JS, HIRSH J: Use of antithrombotic agents during pregnancy. Chest (1998) 114:524S–530S.
   Google Scholar
• GINSBERG JS, GREER I, HIRSH J: Use of antithrombotic agents during pregnancy. Chest (2001) 119(1 Suppl.):1225–1315.
   Google Scholar
• BARB OUR LA, KICK SD, STEINER JF et al.: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. (1994) 170:862–869.
   PubMed Web of Science ®Google Scholar
• CASELE HL, LAIFER SA: Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J. Matern. Fetal Med. (2000) 9:122–125.
   PubMedGoogle Scholar
• BOREL-DERLON A, BORG JY, BOUDIGNET O et al.: Assessment of a LMWH (enoxaparin) safety during pregnancy: a retrospective study of 624
   Google Scholar
• ROWAN JA, MCCOWAN LM, RAUDKIVI PJ, NORTH RA: Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. (2001) 185:633–637.
   PubMed Web of Science ®Google Scholar
• LEV-RAN O, KRAMER A, GUREVITCH J, SHAPIRA I, MOHR R: Low-molecular-weight heparin for prosthetic heart valves: treatment failure. Ann. Thorac. Su. (2000) 69(1):264–265.
   PubMed Web of Science ®Google Scholar
• SALTISSI D, MORGAN C, WESTHUYZEN J, HEALY H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol. Dial. Transplant. (1999) 14:2698–2703.
   PubMed Web of Science ®Google Scholar
• LEIZOROVICZ A, SIMONNEAU G, DECOUSUS H, BOISSEL JP: Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. Br. Med. J (1994) 309:299–304.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of LMWHs showing them to be effective and safe in treatment of DVT.
   Google Scholar
• LEIZOROVICZ A: Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs (1996) 52\(Suppl. 7):30–37.
   Google Scholar
• LENSING AWA, PRINS MH, DAVIDSON BL, HIRSH J: Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch. Intern. Med. (1995) 155:601–607.
   PubMedGoogle Scholar
• SIRAGUSA S, COSMI B, PIOVELLA F, HIRSH J, GINSBERG JS: Low-molecular-weight heparins and unfractionated heparins in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am. J. Med. (1996) 100:269–277.
   PubMed Web of Science ®Google Scholar
• GOULD MK, DEMITZER AD, DOYLE RL, HASTIE TJ, GARBER AM: Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized controlled trials. Ann. Intern. Med. (1999) 130(10):800–809.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDEN JF, HUTTEN BA, BULLER HR, PRINS MH: Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst. Rev. (2000) 4:CD002001.
   Google Scholar
• LEVINE M, GENT M, HIRSH Jet al.: Acomparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl. J Med. (1996) 334:677–681.
   Google Scholar
• MERLI G, SPIRO TE, OLSSON CG et al.: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann. Intern. Med. (2001) 134:191–202.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, CHARBONNIER B, DECOUSUS H et al.: Subcutaneous lowmolecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch. Intern. Med. (1993) 153:1541–1546.
   PubMed Web of Science ®Google Scholar
• SALZMAN EW, DAVIES GC: Prophylaxis of venous thromboembolism: analysis of cost effectiveness. Ann. Su. (1980) 191:207–218.
   PubMed Web of Science ®Google Scholar
• BERGQVIST D, JENDTEG S, JOHANSEN, PERSSON U, ODEGAARD K: Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann. Intern. Med. (1997) 126(6):454–457.
   PubMed Web of Science ®Google Scholar
• HAWKINS DW, LANGLEY PC, KRUEGER KP: Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am. J. Health Syst. Pharm. (1997) 54:1185–1190.
   PubMed Web of Science ®Google Scholar
• BORRIS LC, LASSEN MR: Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective. Drugs (1996) 52\(Suppl. 7):42–46.
   Google Scholar
• DRUMMOND M, ARISTIDES M, DAVIES L, FORBES C: Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br. J. Surg. (1994) 81:1742–1746.
   PubMed Web of Science ®Google Scholar
• MENZIN J, COLDITZ GA, REGAN MM, RICHNER RE, OSTER G: Costeffectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch. Intern. Med. (1995) 155:757–764.
   PubMed Web of Science ®Google Scholar
• DETOURNAY B, PLANES A, VOCHELLE N, FAGNANI F: Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. PharmacoEconomics (1998) 13:81–89.
   PubMed Web of Science ®Google Scholar
• DAVIES LM, RICHARDSON GA, COHEN AT: Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value in Health (2000) 3(6):397–406.
   PubMedGoogle Scholar
• HAWKINS DW, LANGLEY PC, KRUEGER KP: A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. an. Then (1998) 20(1):182–195.
   Google Scholar
• DEVLIN JW, PETITTA A, SHEPARD AD, OBEID FN: Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy (1998) 18(6 I):1335–1342.
   Google Scholar
• WADE WE, CHISHOLM MA: Deep venous thrombosis prophylaxis in trauma: cost analysis. Blood Coagul. Fibrinolysis (2000) 11(1):101–106.
   PubMed Web of Science ®Google Scholar
• PECHEVIS M, DETOURNAY B, PRIBIL C, FAGNANI F, CHALANSON G: Economic evaluation of enoxaparin versus placebo for the prevention of venous thromboembolism in acutely ill medical patients. Value in Health (2000) 3(6):389–396.
   PubMedGoogle Scholar
• DE LISSOVOY G, YUSEN RD, SPIRO TE, KRUPSKI WC, CHAMPION AH, SORENSON SV: Cost for in-patient care of venous thrombosis. A trial of enoxaparin versus standard heparin. Arch. Intern. Med. (2000) 160:3160–3165.
   PubMedGoogle Scholar
• O'BRIEN B, LEVINE M, WILLAN A et al.: Economic evaluation of out-patient treatment with low molecular weight heparin for proximal vein thrombosis. Arch. Intern. Med. (1999) 159(19):2298–2304.
   Google Scholar
• GROCE JB: Patient outcomes and cost analysis associated with an out-patient deep venous thrombosis treatment program. Pharmacotherapy (1998) 18(6 III):175S–180S.
   Google Scholar
• ARDISSINO D, MERLINI PA, ARIENS R, COPPOLA R, BRAMUCCI E, MANNUCCI PM: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet (1997) 349:769-771. 596 Expert Op/n. Pharmacother (2002) 3(5)
   Google Scholar
• TOSCHI V, GALLO R, LETTINO M et al.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 95:594–599.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, HANDIN R: Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation (1998) 98:287–289.
   PubMed Web of Science ®Google Scholar
• ARDISSINO D, MERLINI PA, GAMBA G et al.: Thrombin activity and early outcome in unstable angina pectoris. Circulation (1996) 93:1634–1639.
   PubMed Web of Science ®Google Scholar
• MERLINI PR, BAUER KA, OLTRONA L et al.: Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation (1994) 90:61–68.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, SIMOONS ML, FOX KA et al.: Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur. Heart J. (2000) 21:1406–1432.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA guidelines for the management of patients with unstable angina and nonST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation (2000) 102:1193–1209.
   Google Scholar
• KLEIN W, BUCHWALD A, HILLIS SE et al.: Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragrnin in unstable coronary artery disease study (FRIG). Circulation (1997) 96:61–68.
   Google Scholar
• FRAX.I.S. STUDY GROUP: Comparisonof two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or nonQ wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome). Eur. Heart J. (1999) 20:1553–1562.
   PubMed Web of Science ®Google Scholar
• COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337:447-452. Pivotal phase three study showing enoxaparin 1 mg/kg b.i.d. to be more effective than UFH in preventing recurrent ischemic events in the acute treatment of UA/NSTEMI.
   Google Scholar
• ANTMAN EM, MCCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 100:1593–1601.
   Google Scholar
• •Confirmatory Phase III study, confirming efficicy and safety of enoxaparin 1 mg/kg b.i.d in UA/NSTEMI treatment.
   Google Scholar
• ANTMAN EM, COHEN M, RADLEY D et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation (1999) 100:1602–1608.
   Google Scholar
• GOODMAN SG, COHEN M, BIGONZI F et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in nonQ Wave Coronary Events]. Am. Coll. Cardiol. (2000) 36(3):693–698.
   Google Scholar
• MONTALESCOT G, COLLET JP, LISON Let al.: Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J. Am. Goa Cardiol. (2000) 36(1):110–114.
   Google Scholar
• COHEN M, THEROUX P, FREY MJ et al.: Antithrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation (2000) 102(18)11-826. Abstract.
   Google Scholar
• FOX KAA, ANTMAN E, COHEN M, BIGONZI F, RADLEY D FOR THE ESSENCE/TIMI 11B INVESTIGATORS: Are treatment effects of enoxaparin (low molecular weight heparin) more marked in those undergoing percutaneous intervention (PCI): Results of ESSENCE/TIMI 11B. Eur. Heart J (2000) 21:599. Abstract.
   Google Scholar
• COLLET JP, MONTALESCOT G, LISON L et al.: Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation (2001) 103(5):658–663.
   PubMed Web of Science ®Google Scholar
• RABAH MM, PREMMEREUR J, GRAHAM M et al.: Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am. J. Cardiol. (1999) 84:1391–1395.
   PubMed Web of Science ®Google Scholar
• FAXON DP, SPIRO TE, MINORS et al.: Low molecular weight heparin in prevention of restenosis after angioplasty. Circulation (1994) 90:908–914.
   PubMed Web of Science ®Google Scholar
• ZIDAR JP: Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting. Am. J. Cardiol. (1998) 82:29L–32L.
   Google Scholar
• BATCHELOR WB, MAHAFFEY KW, BERGER PB et al.: A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J. Am. Goa Cardiol. (2001) 38:1608–1613.
   PubMed Web of Science ®Google Scholar
• YOUNG JJ, KEREIAKES DJ, GRINES CL: Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J. Invasive Cardiol. (2000) 12(Suppl. E):E14–E18.
   Google Scholar
• KEREIAKES DJ, GRINES C, FRY E et al.: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invasive Cardiol. (2001) 13(4):272–278.
   PubMedGoogle Scholar
• ••Registry showing evidence of the safety ofenoxaparin and abciximab use during PCI.
   Google Scholar
• FERGUSON JJ, ANTMAN EM, BATES ER et al.: The use of enoxaparin and IIb/ IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study. J. Am. Goa Cardiol. (2001) 37(2 Suppl. 1):1A–648A.
   Google Scholar
• BHATT DL, LINCOFF AM FOR THE CRUISE INVESTIGATORS: Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary interventions: the results of the CRUISE trial. 74th Annual Meeting of the American Heart Association. Anaheim, USA (2001).
   Google Scholar
• GOODMAN SG: The Intergrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes Treatment (INTERACT). 51st Annual Session of the American College of Cardiology. Atlanta, USA (21 March 2002).
   Google Scholar
• ROSS AM, MOLHOEK P, LUNDERGAN C et al.: Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation. (2001) 104(6):648–52.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, KRZEMINSKA-PAKULA M, ALONSO A et al.: Does coronary artery patency improve with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction? Eur. Heart J In press.
   Google Scholar
• ASSENT-3 INVESTIGATORS. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet (2001) 358:605–613.
   Google Scholar
• ••Large Phase II study showing the efficacyand safety of enoxaparin when used as conjunctive therapy to tenecteplase in STEMI patients.
   Google Scholar
• ANTMAN EM, LOUWERENBURG HW, BAARS HF et al.: Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation (2002). Published online March 4, 2002, 10.1161/01.
   Google Scholar
• BALEN RM, MARRA CA, ZED PJ, COHEN M, FRIGHETTO L: Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. PharmacoEconamics (1999) 16(5 II):533–542.
   Google Scholar
• MARK DB, COWPER PA, BERKOWITZ SD et al.: Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation (1998) 97:1702–1707.
   PubMed Web of Science ®Google Scholar
• FOX KAA, BOSANQUET N: Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br. J Cardial. (1998) 5:92–105.
   Google Scholar
• DETOURNAY B, HUET X, FAGNANI F, MONTALESCOT G: Economic evaluation of enoxaparin sodium versus heparin in unstable angina. PharmacoEconamics (2000) 18(1):83–89.
   PubMed Web of Science ®Google Scholar
• LMW heparin safety alert. SCRIP (1997) 2295:15.
   Google Scholar
• Low molecular weight heparin boxed warning will be added to labelling; Rhone-Poulenc Rorer Lovenox reports of hematoma could apply to other LMWHs. FDC Rep Pink Sheet 1997;Dec 22:7.
   Google Scholar
• HORLOCKER TT, HEIT JA: Low molecular weight heparin: biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anesthetic management. Anesth. Analg. (1997) 85:874–885.
   PubMed Web of Science ®Google Scholar
• SANDERINK G, LELIBOUX A, JARIWALA N et al.: Enoxaparin pharmacokinetics and pharmacodynarnics in renal impairment. J Am. Goa Cardial. (2001) 37(2, Suppl. A):229A.
   Google Scholar
• SANDERINK G, LELIBOUX A, JARIWALA N et al.: Enoxaparin pharmacokinetics and pharmacodynarnics in obese. J. Am. Coll. Cardial. (2001) 37(2, Suppl. A):229A.
   Google Scholar
• INVERSO SM, COHEN M, ANTMAN EM, SPINLER SA: Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. J Am. Coll. Cardial. (2001) 37(Suppl. A):365A.
   Google Scholar